MetaVia Inc. filed a Form 8-K on November 12, 2026, disclosing that the company issued a press release announcing additional positive data from the previously reported interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726.

Key Highlights

  • New clinical data: MetaVia announced additional positive data from the interim analysis of Part 3B of its Phase 1 trial of DA-1726.
  • Drug description: DA-1726 is described in the filing as a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors.
  • Disclosure mechanism: The announcement was made via a press release furnished as Exhibit 99.1 and reported under Item 7.01 (Regulation FD).
  • Exchange listing: MetaVia common stock (par value $0.001 per share) trades on NASDAQ:MTVA.
  • Signing officer: The filing was signed by Hyung Heon Kim, President and Chief Executive Officer.

MetaVia Discloses Additional Phase 1 Data for DA-1726 Oxyntomodulin Analog

MetaVia Inc. (NASDAQ:MTVA), headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, filed a current report on November 12, 2026, under Item 7.01 (Regulation FD Disclosures). According to the filing, the company issued a press release on that same date announcing additional positive data from the previously reported interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726.

The filing describes DA-1726 as "a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." The press release containing the full data details is furnished as Exhibit 99.1 and is incorporated into the report by reference. The company disclosed that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," and is therefore not subject to the liabilities of that section.

The filing also notes that it contains forward-looking statements within the meaning of federal securities laws, and that such statements "are based on current expectations and are not guarantees of future performance." The company further stated that "actual events or results may differ materially from those in the forward-looking statements," with additional limitations described in Exhibit 99.1 and in other reports previously filed with the SEC. The report was signed by Hyung Heon Kim, President and Chief Executive Officer, on November 12, 2026.

What Was Disclosed

MetaVia Inc. furnished an 8-K on November 12, 2026, announcing additional positive data from the interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726, a dual GLP-1R and GCGR receptor-targeting oxyntomodulin analog, via a press release attached as Exhibit 99.1.